These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 19500478)
21. Targeted delivery of chemotherapeutic agents using improved radiosensitive liquid core microcapsules and assessment of their antitumor effect. Harada S; Ehara S; Ishii K; Yamazaki H; Matsuyama S; Sato T; Oikawa S; Kamiya T; Arakawa K; Yokota W; Sera K; Ito J Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):455-62. PubMed ID: 19735868 [TBL] [Abstract][Full Text] [Related]
22. Luciferase therapeutic microcapsules for gene therapy. Li AA; Hou DY; Shen F; Seidlitz EP; Potter MA Artif Cells Blood Substit Immobil Biotechnol; 2009; 37(6):235-44. PubMed ID: 19922164 [TBL] [Abstract][Full Text] [Related]
23. Potentiation of cytochrome P450/cyclophosphamide-based cancer gene therapy by coexpression of the P450 reductase gene. Chen L; Yu LJ; Waxman DJ Cancer Res; 1997 Nov; 57(21):4830-7. PubMed ID: 9354446 [TBL] [Abstract][Full Text] [Related]
24. Frequent, moderate-dose cyclophosphamide administration improves the efficacy of cytochrome P-450/cytochrome P-450 reductase-based cancer gene therapy. Jounaidi Y; Waxman DJ Cancer Res; 2001 Jun; 61(11):4437-44. PubMed ID: 11389073 [TBL] [Abstract][Full Text] [Related]
25. Necrotic, rather than apoptotic, cell death caused by cytochrome P450-activated ifosfamide. Karle P; Renner M; Salmons B; Günzburg WH Cancer Gene Ther; 2001 Mar; 8(3):220-30. PubMed ID: 11332993 [TBL] [Abstract][Full Text] [Related]
26. Injection of encapsulated cells producing an ifosfamide-activating cytochrome P450 for targeted chemotherapy to pancreatic tumors. Müller P; Jesnowski R; Karle P; Renz R; Saller R; Stein H; Püschel K; von Rombs K; Nizze H; Liebe S; Wagner T; Günzburg WH; Salmons B; Löhr M Ann N Y Acad Sci; 1999 Jun; 880():337-51. PubMed ID: 10415878 [TBL] [Abstract][Full Text] [Related]
27. Enantioselective metabolism and cytotoxicity of R-ifosfamide and S-ifosfamide by tumor cell-expressed cytochromes P450. Chen CS; Jounaidi Y; Waxman DJ Drug Metab Dispos; 2005 Sep; 33(9):1261-7. PubMed ID: 15919850 [TBL] [Abstract][Full Text] [Related]
28. Continuous and high-level in vivo delivery of endostatin from recombinant cells encapsulated in TheraCyte immunoisolation devices. Malavasi NV; Rodrigues DB; Chammas R; Chura-Chambi RM; Barbuto JA; Balduino K; Nonogaki S; Morganti L Cell Transplant; 2010; 19(3):269-77. PubMed ID: 19951460 [TBL] [Abstract][Full Text] [Related]
29. Targeted intraabdominal chemotherapy for peritoneal carcinomatosis. Samel S; Löhr M Cancer Treat Res; 2007; 134():469-82. PubMed ID: 17633075 [TBL] [Abstract][Full Text] [Related]
30. Polyelectrolyte microcapsule interactions with cells in two- and three-dimensional culture. An Z; Kavanoor K; Choy ML; Kaufman LJ Colloids Surf B Biointerfaces; 2009 Apr; 70(1):114-23. PubMed ID: 19162453 [TBL] [Abstract][Full Text] [Related]
31. Competing two enzymatic reactions realizing one-step preparation of cell-enclosing duplex microcapsules. Ashida T; Sakai S; Taya M Biotechnol Prog; 2013; 29(6):1528-34. PubMed ID: 23955874 [TBL] [Abstract][Full Text] [Related]
32. Progress technology in microencapsulation methods for cell therapy. Rabanel JM; Banquy X; Zouaoui H; Mokhtar M; Hildgen P Biotechnol Prog; 2009; 25(4):946-63. PubMed ID: 19551901 [TBL] [Abstract][Full Text] [Related]
33. Impact of liver P450 reductase suppression on cyclophosphamide activation, pharmacokinetics and antitumoral activity in a cytochrome P450-based cancer gene therapy model. Huang Z; Raychowdhury MK; Waxman DJ Cancer Gene Ther; 2000 Jul; 7(7):1034-42. PubMed ID: 10917206 [TBL] [Abstract][Full Text] [Related]
34. Strong inhibition of Ewing tumor xenograft growth by combination of human interferon-alpha or interferon-beta with ifosfamide. Sancéau J; Poupon MF; Delattre O; Sastre-Garau X; Wietzerbin J Oncogene; 2002 Oct; 21(50):7700-9. PubMed ID: 12400012 [TBL] [Abstract][Full Text] [Related]
35. Intratumoral injection of encapsulated cells producing an oxazaphosphorine activating cytochrome P450 for targeted chemotherapy. Karle P; Müller P; Renz R; Jesnowski R; Saller R; von Rombs K; Nizze H; Liebe S; Günzburg WH; Salmons B; Löhr M Adv Exp Med Biol; 1998; 451():97-106. PubMed ID: 10026857 [TBL] [Abstract][Full Text] [Related]
36. Intraneoplastic polymer-based delivery of cyclophosphamide for intratumoral bioconversion by a replicating oncolytic viral vector. Ichikawa T; Petros WP; Ludeman SM; Fangmeier J; Hochberg FH; Colvin OM; Chiocca EA Cancer Res; 2001 Feb; 61(3):864-8. PubMed ID: 11221871 [TBL] [Abstract][Full Text] [Related]
37. Sustained and therapeutic levels of human factor IX in hemophilia B mice implanted with microcapsules: key role of encapsulated cells. Wen J; Vargas AG; Ofosu FA; Hortelano G J Gene Med; 2006 Mar; 8(3):362-9. PubMed ID: 16311997 [TBL] [Abstract][Full Text] [Related]
39. Cytosine deaminase-producing human mesenchymal stem cells mediate an antitumor effect in a mouse xenograft model. You MH; Kim WJ; Shim W; Lee SR; Lee G; Choi S; Kim DY; Kim YM; Kim H; Han SU J Gastroenterol Hepatol; 2009 Aug; 24(8):1393-400. PubMed ID: 19486256 [TBL] [Abstract][Full Text] [Related]
40. Indefinite islet protection from autoimmune destruction in nonobese diabetic mice by agarose microencapsulation without immunosuppression. Kobayashi T; Aomatsu Y; Iwata H; Kin T; Kanehiro H; Hisanaga M; Ko S; Nagao M; Nakajima Y Transplantation; 2003 Mar; 75(5):619-25. PubMed ID: 12640299 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]